Dallas K. Croom
Research Triangle Park Foundation(US)GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Neuropeptides and Animal Physiology, Diabetes Treatment and Management, Receptor Mechanisms and Signaling, Peptidase Inhibition and Analysis, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis(2000)140 cited
- → Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”(1996)101 cited
- → Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes(2011)97 cited
- → Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments(2004)88 cited
- → Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists(1997)86 cited
- → Synthesis, Topoisomerase I Inhibitory Activity, and in Vivo Evaluation of 11-Azacamptothecin Analogs(1995)55 cited
- → Structure-Based Design of Potent Retinoid X Receptor α Agonists(2004)48 cited
- → Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase by 6-Azaandrost-4-en-3-ones: Optimization of the C17 Substituent(1995)47 cited
- → Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II): Optimization of the C3 Amino Substituent(1996)37 cited
- → Water Soluble Inhibitors of Topoisomerase I: Quaternary Salt Derivatives of Camptothecin(1996)34 cited